Tyler A. Longmire

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (United States) · ORCID：0000-0002-1621-1895

发表论文 56 篇 · 总被引 1613 次 · h-index 13

代表论文

• Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells (2012 · Cell stem cell · 被引 397)
• Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021 · Clinical Cancer Research · 被引 369)
• Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies (2022 · Journal for ImmunoTherapy of Cancer · 被引 162)
• Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (2019 · Blood · 被引 88)
• Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment (2021 · Cancer Research · 被引 62)
• Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor (2022 · Immunotherapy Advances · 被引 50)